Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years.
García-Velasco A, Zacarías-Pons L, Teixidor H, Valeros M, Liñan R, Carmona-Garcia MC, Puigdemont M, Carbajal W, Guardeño R, Malats N, Duell E, Marcos-Gragera R. García-Velasco A, et al. Among authors: guardeno r. Int J Environ Res Public Health. 2020 Dec 19;17(24):9538. doi: 10.3390/ijerph17249538. Int J Environ Res Public Health. 2020. PMID: 33352812 Free PMC article.
Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.
Puig-Costa M, Codina-Cazador A, Cortés-Pastoret E, Oliveras-Ferraros C, Cufí S, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Corominas-Faja B, Cuyàs E, Ortiz R, Lopez-Bonet E, Queralt B, Guardeño R, Martin-Castillo B, Roig J, Joven J, Menendez JA. Puig-Costa M, et al. Among authors: guardeno r. Oncotarget. 2014 Apr 15;5(7):1942-54. doi: 10.18632/oncotarget.1879. Oncotarget. 2014. PMID: 24722433 Free PMC article.
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: guardeno r. Int J Oncol. 2011 Dec;39(6):1455-79. doi: 10.3892/ijo.2011.1155. Epub 2011 Aug 9. Int J Oncol. 2011. PMID: 21833472
Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.
Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: guardeno r. J Cell Biochem. 2011 Jan;112(1):10-29. doi: 10.1002/jcb.22952. J Cell Biochem. 2011. PMID: 21104905
Clinical guideline SEOM: hepatocellular carcinoma.
Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Sastre J, et al. Among authors: guardeno r. Clin Transl Oncol. 2015 Dec;17(12):988-95. doi: 10.1007/s12094-015-1451-3. Epub 2015 Nov 25. Clin Transl Oncol. 2015. PMID: 26607931 Free PMC article.
Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A. Laquente B, et al. Among authors: guardeno r. BMC Palliat Care. 2020 Jul 10;19(1):103. doi: 10.1186/s12904-020-00610-4. BMC Palliat Care. 2020. PMID: 32650765 Free PMC article.
Blindness in a bladder cancer patient.
Remón J, Guardeño R, Badía A, Cardona T, Picaza JM, Lianes P. Remón J, et al. Among authors: guardeno r. Clin Transl Oncol. 2007 Feb;9(2):117-8. doi: 10.1007/s12094-007-0022-7. Clin Transl Oncol. 2007. PMID: 17329224
Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma.
Soria A, Calvo M, Casas M, Vidales Z, Muñoz-Martínez S, Sapena V, Puigvehi M, Canillas L, Guardeño R, Gallego A, Mínguez B, Horta D, Clos A, Montoliu S, Roget M, Reig M, Vergara M. Soria A, et al. Among authors: guardeno r. Front Oncol. 2022 Aug 2;12:829483. doi: 10.3389/fonc.2022.829483. eCollection 2022. Front Oncol. 2022. PMID: 35982971 Free PMC article.
14 results